Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases
The efficacy of NAT for RPC might be limited to the subset of patients with high TM.
Authors
- Hideyuki Dei (ORCID: https://orcid.org/0000-0002-5091-5036)
- Katsuhiko Uesaka
- Ryo Ashida (ORCID: https://orcid.org/0000-0001-8388-0135)
- Kentaro Yamazaki (ORCID: https://orcid.org/0000-0001-6269-9345)
- Teiichi Sugiura (ORCID: https://orcid.org/0000-0001-7163-4084)
- Yoshiyasu Kato (ORCID: https://orcid.org/0000-0002-2203-256X)
- Shimpei Otsuka (ORCID: https://orcid.org/0000-0002-2450-3011)
- Katsuhisa Ohgi (ORCID: https://orcid.org/0000-0003-1647-1117)
Institutions
- Shizuoka Cancer Center (JP)
Publication Details
- Journal
- Pancreas
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1097/mpa.0000000000002485
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14